Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our market websites.
-
GSK exercises option on phase I/II NY-ESO T-cell therapy (GSK3377794)
Today GSK announced that it has exercised the option to obtain an exclusive global license from Adaptimmune for an investigational SPEAR T-cell receptor therapy targeting NY-ESO...
Read more -
GSK presents respiratory data from pipeline to clinical practice at ERS
45 abstracts will be shared adding to clinical and scientific knowledge about current and future treatments for patients with respiratory diseases
Read more -
GSK responds to UK Life Sciences Industrial Strategy
Read our response to the UK Life Sciences Industrial Strategy.
Read more -
GSK delivers further progress in Q2 and sets out new priorities for the Group
Q2 was another quarter of progress for GSK with Group sales up 3% to £7.3 billion and Adjusted EPS of 27.2p.
Read more -
Karenann Terrell appointed Chief Digital & Technology Officer, GSK
GSK today announced that Karenann Terrell has been appointed Chief Digital & Technology Officer
Read more -
ViiV Healthcare announces superior efficacy of dolutegravir versus lopinavir/ritonavir in second-line HIV treatment in resource-limited settings
ViiV Healthcare, the global specialist HIV company, majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive interim results from D...
Read more -
Switching to a dolutegravir regimen from a boosted protease inhibitor regimen maintained viral suppression and improved lipid fractions in patients with HIV and high cardiovascular risk
ViiV Healthcare and NEAT-ID announced results from the NEAT 022 study of more than 400 patients with HIV and high cardiovascular risk
Read more -
Phase II study results showed comparable viral suppression rates at 96 weeks for a two-drug regimen of long-acting cabotegravir and rilpivirine and a three-drug regimen in patients with HIV
LATTE-2 study results published in The Lancet and presented at International AIDS Society Meeting
Read more -
GSK submits US regulatory filing of Arnuity Ellipta in children with asthma
GSK today announced the filing of a supplementary New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for the use of Arnuity Ellipta (fluticasone furoate) a...
Read more -
GSK announces Board and Committee changes
GSK today announces that Dr Laurie Glimcher has been appointed to the Board of the Company as a Non-Executive Director and has been deemed a Scientific and Medical Expert.
Read more -
GSK submits EU filing for extended use of Relvar Ellipta in patients with controlled asthma on an ICS/LABA combination
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced a submission to the European Medicines Agency (EMA) for the extended use of once-daily Relv...
Read more -
GSK receives FDA approval for a new self-injectable formulation of Benlysta (belimumab) for systemic lupus erythematosus
GSK announced today that the US Food and Drug Administration (FDA) has approved a new subcutaneous formulation of Benlysta (belimumab) for the treatment of adult patients with a...
Read more -
ViiV Healthcare shares data from its innovative portfolio with HIV community at IAS 2017
ViiV Healthcare shares data from its innovative portfolio with HIV community at IAS 2017
Read more -
GSK updates on UK manufacturing network
GSK today set out several announcements made by the company to improve the efficiency and competitiveness of its manufacturing network.
Read more -
GSK announces US regulatory submission for mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA)
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the submission of a supplemental Biologics License Application (sBLA) to the United States Food and Drug Administration (FDA)...
Read more -
GSK starts phase III study with mepolizumab in patients with nasal polyps
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the start of a phase III study with mepolizumab, an interleukin 5 (IL-5) antagonist, in patients with severe bilateral nasal ...
Read more -
GSK receives CHMP positive opinion for Synflorix pneumococcal vaccine four-dose vial
New presentation designed to significantly reduce storage requirements in developing countries.
Read more -
GSK presents positive results from Phase III revaccination study of its candidate shingles vaccine Shingrix at CDC’s Advisory Meeting
Study conducted in individuals who had previously received current standard of care
Read more -
GSK announces results from 10-year continuation study showing sustained disease control with Benlysta (belimumab) in SLE
GSK today announced results from a 10-year continuation study, which showed that Benlysta (belimumab) plus standard of care prolonged control of disease activity in patients wit...
Read more -
GSK and MMV announce positive headline phase III results showing single-dose tafenoquine reduces risk of relapse in patients with Plasmodium vivax malaria
GSK and Medicines for Malaria Venture (MMV) today announced positive results from two phase III studies of tafenoquine, an investigational 8-aminoquinoline, for the prevention o...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose to improve the quality of human life.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines & consumer healthcare from inside and outside our labs. Go #BehindTheScience to see for yourself
